Format

Send to

Choose Destination
J Biopharm Stat. 2017;27(2):197-205. doi: 10.1080/10543406.2016.1272606. Epub 2016 Dec 15.

Development of statistical methods for analytical similarity assessment.

Author information

1
a Office of Biostatistics, Office of Translational Science, CDER, FDA , Silver Spring , Maryland , USA.
2
b Global Biostatistical Science, Amgen Inc. , Washington , DC , USA.

Abstract

To evaluate the analytical similarity between the proposed biosimilar product and the US-licensed reference product, a working group at Food and Drug Administration (FDA) developed a tiered approach. This proposed tiered approach starts with a criticality determination of quality attributes (QAs) based on risk ranking of their potential impact on product quality and the clinical outcomes. Those QAs characterize biological products in terms of structural, physicochemical, and functional properties. Correspondingly, we propose three tiers of statistical approaches based on the levels of stringency in requirements. The three tiers of statistical approaches will be applied to QAs based on the criticality ranking and other factors. In this article, we discuss the statistical methods applicable to the three tiers of QA. We further provide more details for the proposed equivalence test as the Tier 1 approach. We also provide some discussion on the statistical challenges of the proposed equivalence test in the context of analytical similarity assessment.

KEYWORDS:

Analytical similarity; equivalence test; quality attribute; tiered approach

PMID:
27977326
DOI:
10.1080/10543406.2016.1272606
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center